⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025Open Access

Figure S5 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Kunling Chen Huolun Feng Y. Zhang Jingyuan Pei Yuyan Xu Xiangxu Wei Zhuohao Chen Zhoubin Feng Lei Cai Yong Li Liang Zhao Mingxin Pan

View Full Paper

Ask AI

Bookmark

Share

Key Points

CCL16 treatment improves tumor vasculature, enhancing immunotherapy outcomes in hepatocellular carcinoma.
Significant changes in macrophage icam-1 expression were observed following CCL16 exposure.
The study utilized in vitro assessments to determine the mechanistic role of CCL16 in modulating macrophage activity.
These findings highlight the potential of targeting ccl16 to optimize cancer immunotherapy strategies.

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Implication

Analysis reveals CCL16's effect on macrophage icam-1, indicating enhanced immunotherapy in hepatocellular carcinoma.

Abstract

The role of macrophage membrane receptor ICAM-1.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21afd https://doi.org/10.1158/0008-5472.30254932

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S6 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
2Figure S2 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
3Figure S7 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
4Figure S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
5Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025

Figure S9 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S3 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025